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A Pilot Stability Study of Dehydroepiandrosterone Rapid-dissolving Tablets
Prepared by Extemporaneous Compounding
Abstract
Dehydroepiandrosterone supplementation is used to treat a variety of conditions. Rapid-dissolving tablets
are a relatively novel choice for compounded dehydroepiandrosterone dosage forms. While rapiddissolving tablets offer ease of administration, there are uncertainties about the physical and chemical
stability of the drug and dosage form during preparation and over long-term storage. This study was
designed to evaluate the stability of dehydroepiandrosterone rapid-dissolving tablets just after
preparation and over six months of storage. The Professional Compounding Centers of America rapiddissolving tablet mold and base formula were used to prepare 10-mg strength dehydroepiandrosterone
rapid-dissolving tablets. The formulation was heated at 100°C to 110°C for 30 minutes, released from the
mold, and cooled at room temperature for 30 minutes. The resulting rapid-dissolving tablets were
individually packaged in amber blister packs and stored in a stability chamber maintained at 25°C and
60% relative humidity. The stability samples were pulled at pre-determined time points for evaluation,
which included visual inspection, tablet weight check, United States Pharmacopeia disintegration test,
and stability-indicating high-performance liquid chromatography. The freshly prepared
dehydroepiandrosterone rapiddissolving tablets exhibited satisfactory chemical and physical stability.
Time 0 samples disintegrated within 40 seconds in water kept at 37°C. The highperformance liquid
chromatographic results confirmed that the initial potency was 101.9% of label claim and that there was
no chemical degradation from the heating procedure. Over six months of storage, there were no
significant changes in visual appearance, physical integrity, or disintegration time for any of the stability
samples. The high-performance liquid chromatographic results also indicated that
dehydroepiandrosterone rapid-dissolving tablets retained >95% label claim with no detectable
degradation products. The dehydroepiandrosterone rapid-dissolving tablets investigated in this pilot study
were physically and chemically stable during preparation and over six months of storage at 25°C and 60%
relative humidity.
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A Pilot Stability Study of Dehydroepiandrosterone
Rapid-dissolving Tablets Prepared by
Extemporaneous Compounding
ABSTRACT
Dehydroepiandrosterone supplementation is used to treat a variety of
conditions. Rapid-dissolving tablets are a relatively novel choice for
compounded dehydroepiandrosterone dosage forms. While rapid-dissolving
tablets offer ease of administration, there are uncertainties about the physical
and chemical stability of the drug and dosage form during preparation and
over long-term storage. This study was designed to evaluate the stability of
dehydroepiandrosterone rapid-dissolving tablets just after preparation and
over six months of storage. The Professional Compounding Centers of America
rapid-dissolving tablet mold and base formula were used to prepare 10-mg
strength dehydroepiandrosterone rapid-dissolving tablets. The formulation
was heated at 100°C to 110°C for 30 minutes, released from the mold, and
cooled at room temperature for 30 minutes. The resulting rapid-dissolving
tablets were individually packaged in amber blister packs and stored in a
stability chamber maintained at 25°C and 60% relative humidity. The stability
samples were pulled at pre-determined time points for evaluation, which
included visual inspection, tablet weight check, United States Pharmacopeia
disintegration test, and stability-indicating high-performance liquid
chromatography. The freshly prepared dehydroepiandrosterone rapiddissolving tablets exhibited satisfactory chemical and physical stability. Time 0
samples disintegrated within 40 seconds in water kept at 37°C. The highperformance liquid chromatographic results confirmed that the initial potency
was 101.9% of label claim and that there was no chemical degradation from the
heating procedure. Over six months of storage, there were no significant
changes in visual appearance, physical integrity, or disintegration time for any
of the stability samples. The high-performance liquid chromatographic results
also indicated that dehydroepiandrosterone rapid-dissolving tablets retained
>95% label claim with no detectable degradation products. The
dehydroepiandrosterone rapid-dissolving tablets investigated in this pilot
study were physically and chemically stable during preparation and over six
months of storage at 25°C and 60% relative humidity.
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INTRODUCTION
Dehydroepiandrosterone (DHEA) is an
important steroid produced primarily by
the adrenal gland. Its chemical structure
is shown in Figure 1. DHEA and its sulfate
conjugate (DHEAS) are the most abundant
circulating steroid hormones in the body
and serve as a reservoir for the biosynthesis of other more potent sex hormones,
such as testosterone and estradiol.1-3

F I G U R E 1 . CHEMICAL STRUCTURE OF
DEHYDROEPIANDROSTERONE.
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Recent studies reveal that DHEA is a
neurosteroid with important functions in
the mammalian brains.4-6 Levels of DHEA
and DHEAS peak in early adulthood and
decline steadily afterwards at a rate of
about 10% per decade.2 Supplementation
of DHEA has been proposed to treat a wide
variety of conditions, such as sexual dysfunction, decline in cognitive functions,
osteoporosis, and infertility.2,7-9 However,
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F I G U R E 2 . APPEARANCE OF RAPID-DISSOLVING TABLETS AFTER THEY ARE RELEASED FROM THE MOLD.
many claims are still
awaiting evidence
from adequately
powered, long-term
clinical trials. DHEA
is regulated as a
dietary supplement
in the U.S., and commercial products
are available as oral
capsules/tablets,
intra-oral spray, and
transdermal creams/
gels. However, quality issues of these
commercial products
have been revealed
by independent
laboratory analysis,
and patients are recommended to obtain
DHEA supplements
from compounding
pharmacies.2
With the recent
introduction of
This pilot study was designed to evaluate the chemical and
special molds and base formulas, rapid-dissolving tabphysical
stability of a representative DHEA RDT formulation imlets (RDTs) are gaining popularity among compounded
mediately
after preparation and over six months of storage. Such
dosage forms. DHEA in RDT dosage forms can offer ease
information
will aid the compounding pharmacists in establishing
of administration for general patients and serve as an efproper
storage
conditions and beyond-use dates of similar DHEA
fective option for patients who cannot swallow tablets or
RDT
preparations.
have absorption issues (e.g., due to gastric bypass). However, the new excipients, compounding methods, and
physical properties of RDTs are significantly different
MATERIALS AND METHODS
from those of the conventional solid dosage forms, such
MATERIALS
as compressed tablets or hard-gelatin capsules. There
are new uncertainties about the drug and dosage form
All ingredients for the RDTs were purchased from Professional
Compounding Centers of America (PCCA) (Houston, Texas), and
stability during preparation and over long-term storage.
they include DHEA micronized powder
(Cat 55-2960), RDT powder base (Cat
T A B L E 1 . DEHYDROEPIANDROSTERONE RAPID-DISSOLVING TABLET FORMULA.
30-3269), steviol glycosides (Cat 30-4539),
acesulfame potassium (Cat 30-4398),
A MO UN T P E R B A T C H
and peppermint oil flavor (Cat 30-3462).
IN GREDIENT
A M OU NT PER RDT
(96 R D T S)
The 96-cavity RDT mold (Cat 35-3791)
DHEA micronized powder
10 mg
0.960 g
and the blister packs with adhesive label
RDT base powder
625 mg
59.992 g
backing (Cat 35-2512 and Cat 35-2671)
Steviol glycosides
3 mg
0.288 g
were also obtained from PCCA. For
Acesulfame potassium
4 mg
0.384 g
high-performance liquid chromatograPeppermint oil flavor
~0.04 drop
4 drops
phy (HPLC) analysis, a reference stanTotal (excluding flavor)
642 mg
61.6 g
dard of DHEA bulk drug substance (Lot
A0329093; Cat AC154980100), 0.45-µm
DHEA = dehydroepiandrosterone; RDT = rapid-dissolving tablet
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The formula of 10-mg DHEA RDTs is listed in Table 1. In addition to the drug and RDT base, small amounts of two artificial
sweeteners and a flavor were included. For each batch preparation, the ingredients were mixed thoroughly and press-filled into
the cavities of a RDT mold. The filled RDT mold was heated in a
convection oven at 100°C to 110°C for 30 minutes. The resulting
RDTs were cooled to room temperature and immediately released
from the mold. A representative picture of the RDTs at this stage
is shown in Figure 2. The RDTs were cooled for an additional 30
minutes, packaged into blister packs, and sealed with an adhesive
label backing.

STABILITY STUDY
For the stability study evaluation, the packaged RDTs were
stored in a stability chamber maintained at 25°C ± 2ºC and 60% ±
5% relative humidity (RH). Samples were withdrawn for analysis
at 0, 2, 4, 9, 13, and 26 weeks. At each time point, twelve RDTs were
taken out of the blister packs and subjected to visual inspection
for color, shape, and physical defects. Their weights were also
measured to monitor any potential moisture uptake. Six RDTs
were then analyzed by the United States Pharmacopeia (USP)
disintegration test, using a Varian VK 100 model (Cary, North
Carolina) with water as the media.10 Three RDTs were analyzed by
the stability-indicating HPLC method described below.

HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY
The HPLC analysis was performed using a model LC-2010A system with LC Solution software from Shimadzu Scientific Instruments (Marlborough, Massachusetts). A Hypersil ODS-2 C18 column (150 × 4.6 mm, 5 µ) from Fisher Scientific (Cat 31605154630)
was used and maintained at 30ºC. The mobile phase consisted of
acetonitrile:water 45:55 (v/v), and the flow rate was 0.8 mL/min.
The sample injection volume was 25 µL, and the ultraviolet detection was set at 207 nm. Under these HPLC conditions, the retention time of the drug was approximately 8.0 min. A representative
HPLC chromatogram is shown in Figure 3.
For the potency and stability analysis, three RDTs from each
time point were aggregated and crushed to a fine powder in a glass
mortar and pestle. Three samples of about one-half tablet weight
were weighed out and placed in to Class-A, 25-mL volumetric
flasks. The flasks were brought to volume with the mobile phase,
and the nominal DHEA concentration was about 0.2 mg/mL. The
samples were shaken vigorously for the drug to fully dissolve. Ap-
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mAu

FORCED DEGRADATION STUDY
40

In order to verify that the above HPLC method was stability indicating, four DHEA solution samples at 0.2 mg/mL were prepared for
a forced20degradation study. Samples 1 and 2 were adjusted to pH 2
and 12 with hydrochloric acid and sodium hydroxide, respectively.
Samples 3 and 4 were each spiked with hydrogen peroxide for a final
concentration
of 3%. Samples 1 through 3 were incubated at 60ºC in
0
a convection oven, and Sample 4 was kept on a windowsill (ambient
room temperature) and exposed to direct sunlight.
0
10
All four samples
were analyzed at initial
time, 3 hours, 24 hours, 20
72 hours, and 7 days using the HPLC
Time method
(Minutes)described above. No
mAu

RAPID-DISSOLVING TABLETS FORMULA AND
COMPOUNDING

proximately
a 2-mL aliquot of each sample was withdrawn and fil40
tered through a PVDF 0.45-µm syringe filter into an HPLC vial for
analysis. Each sample was analyzed by three replicate injections.
The average
DHEA RDT potency and percent label claims were
20
calculated for each stability time point. The HPLC chromatograms
were also carefully inspected for potential degradation products.
0
For calibration
purpose, DHEA standard solutions were
prepared at 0.12, 0.16, 0.20, 0.24, and 0.28 mg/mL. A five-point
standard 0curve was generated on each10analysis day. The curves 20
were found to be linear over the concentration range of the
Time (Minutes)
standards with a regression coefficient
(r) of 0.99 or better. The
precision of the method was established by multiple injections of
the mid-point standard (0.2 mg/mL) throughout each analysis day.
The intra-day
and inter-day coefficients of variation were within
80
0.2% and 1.1%, respectively. Additionally, a blank RDT sample was
prepared and analyzed on each analysis day to confirm that there
was no60
interference from the RDT excipients.

F I G U R E 3 . A REPRESENTATIVE HIGH-PERFORMANCE LIQUID
CHROMATOGRAM OF 0.2-MG/ML DEHYDROEPIANDROSTERONE.
400
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PVDF syringe filters, and acetonitrile (Cat A998-4) were purchased from Fisher Scientific (Hanover Park, Illinois); Type I
purified water was obtained using a Milli-Q system from Millipore
(Billerica, Massachusetts).
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significant degradation was observed for Samples 1 or 2 after
7 days. Sample 3 degraded by 62% after 3 hours, and Sample 4
degraded by 91% after 7 days. The degradation peaks in both
samples were well separated from that of the parent drug. Based
on these results, the HPLC method was considered as stability
indicating and deemed suitable for the proposed stability study
of the DHEA RDTs.

RESULTS AND DISCUSSION
The DHEA RDT formulation exhibited satisfactory chemical
and physical stability during the compounding process. All
resulting RDTs appeared as white and round tablets with no
visible physical defects. The weight of twelve RDT samples
averaged 637 mg (99.2% nominal value). The disintegrate time
of the six RDTs ranged from 5 seconds to 40 seconds. The HPLC
results showed that the initial potency was 101.9% of label claim.
No new peaks were observed in the HPLC chromatograms,
which suggested that DHEA, in this solid RDT formulation, was
chemically stable against the 30-minute heating process at 100°C
to 110°C employed during compounding.
Over 26 weeks (six months) of storage at 25°C/60% RH, the
visual appearance remained mostly unchanged, and all stability
samples retained their physical integrity with no obvious visual
defects. No significant tablet weight gain was observed, suggesting that there was minimal moisture uptake by the DHEA RDTs
in the blister packs. The disintegration time also remained at 5
seconds to 40 seconds for all stability samples. As shown in Table
2, the HPLC results indicated that DHEA RDTs retained >95% of
label claim throughout the six months of storage. No significant
degradation products were detected by the stability-indicating
HPLC method.
According to USP <795>, in the absence of established stability data, the beyond-use date is recommended as 180 days (~ six
months) for non-aqueous formulations.11 RDTs are a relatively
new dosage form which may present unique stability challenges
chemically and physically. For example, the compounding method
for the formulation used in this study involves heating at 100°C to
110°C, which is not typically used in compounding conventional
solid dosage forms such as powders or capsules. Heating can lead
to potential chemical instability of the drug and physical form
change (e.g., crystalline to amorphous). By design, the RDT matrix
is presumably more hygroscopic and porous than traditional compressed tablets. The increased exposure to moisture and oxygen
may also accelerate drug degradation during storage. With these
considerations, it is prudent to conduct a stability study on a new
drug RDT formulation and generate actual data to support the
beyond-use date.
The results from this pilot study confirmed that DHEA in the
current RDT formulation is chemically stable against the heating
step at 100°C to 110°C during compounding and remains stable
over six months of storage at 25°C/60% RH. The additional data
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T A B L E 2 . HIGH-PERFORMANCE LIQUID
CHROMATOGRAPHY RESULTS OF
DEHYDROEPIANDROSTERONE RAPID-DISSOLVING
TABLETS STABILITY SAMPLES.
T I ME (WE E K )

% L A B E L C L A I M*

0

101.9 ± 0.32

2

101.0 ± 3.01

4

103.8 ± 2.95

9

100.2 ± 1.32

13

96.8 ± 0.33

26

99.4 ± 1.50

*Mean ± standard deviation (n=3)

from visual inspection, weight check, and disintegration test also
verified that the DHEA RDTs retained their physical integrity and
rapid-dissolving property during this storage period.
Several limitations of this study should be pointed out. This
study evaluated only the RDT base formula and packaging materials from one commercial supplier. The recommended storage
condition was limited to one temperature/humidity. Finally, the
disintegration test only confirmed that the tablet, not necessarily the drug, was dissolving rapidly in an aqueous environment.
Nevertheless, the results from this pilot study will be useful for the
design of a comprehensive stability study in the future.

CONCLUSION
A pilot stability study was conducted on the 10-mg strength
DHEA RDTs prepared using the RDT base formula and mold
from PCCA. The DHEA RDTs was found to be stable chemically
and physically during the compounding procedures and over six
months of storage at 25°C and 60% RH.
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